Liposomal formulation for dermal and transdermal drug delivery: Past, present and future

Recent Patents on Drug Delivery and Formulation

Volumn 2, Issue 1, 2008, Pages 9-18

  Nounou, Mahmoud M ^a,b   El Khordagui, Labiba K ^b   Khalafallah, Nawal A ^b   Khalil, Said A ^b  

^a UNIVERSITY OF HOUSTON   (United States)

^b Alexandria University Faculty of Pharmacy   (Egypt)

Author keywords

Catezomes; Dermal drug delivery; Drug targeting; Ethosomes; MLVs; Niosomes; SPLVs; Traditional liposomes; Transdermal drug delivery; Transfersomes

Indexed keywords

ALPHA INTERFERON; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTINEOPLASTIC AGENT; BENZOYL PEROXIDE; DEXAMETHASONE; ECONAZOLE; EPIDERMAL GROWTH FACTOR; ESTRADIOL; FLUOROURACIL; HYDROCORTISONE; IMMUNOLIPOSOME; INSULIN; INTERFERON; INTERLEUKIN 2; LEPROSTATIC AGENT; LIPOSOME; LOCAL ANESTHETIC AGENT; METHOTREXATE; MICROSPHERE; MINOXIDIL; NIOSOME; PLASMID DNA; PONTOPANE; PROGESTERONE; RETINOIC ACID; TESTOSTERONE; TETRACAINE; TRIAMCINOLONE ACETONIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VITAMIN;

ACNE; ARTICLE; CLINICAL TRIAL; CREAM; DERMATOMYCOSIS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG PENETRATION; DRUG TISSUE LEVEL; DRUG TRANSPORT; ELECTROPORATION; ENCAPSULATION; GEL; HERPES SIMPLEX; HIRSUTISM; HUMAN; HYDROCOLLOID; IONTOPHORESIS; LIPOSOMAL DELIVERY; LIPOSOMAL GENE DELIVERY SYSTEM; LOTION; NONHUMAN; PASTE; PRIORITY JOURNAL; PSORIASIS; SINGLE DRUG DOSE; SKIN DISEASE; SKIN INJURY; SKIN SURFACE; SUSTAINED DRUG RELEASE; TOPICAL ANESTHESIA; TOPICAL TREATMENT; TRANSDERMAL PATCH;

ADMINISTRATION, CUTANEOUS; ANIMALS; DELAYED-ACTION PREPARATIONS; DRUG DELIVERY SYSTEMS; HUMANS; LIPOSOMES; PATENTS AS TOPIC; PHARMACEUTICAL PREPARATIONS; SKIN; SKIN ABSORPTION;

EID: 42249085107     PISSN: 18722113     EISSN: None     Source Type: Journal    
DOI: 10.2174/187221108783331375     Document Type: Article

References (102)

1. Walters KA. Drug Delivery: Topical and Transdermal Routes, in Encyclopedia of Pharmaceutical Technology, J. C. Boylan, Editor. Marcel Dekker: New York. 2002.
2. Roberts M, Cross SE, Pellett MA. Skin transport., in Encyclopedia of Pharmaceutical Technology, Boylan JC. Editor. 1988; Marcel Dekker: New York. 89-195.
3. Barry BW. Lipid-Prolein-Partitioning theory of skin penetration enhancement: J Control Release 1991; 15(3): 237-248.
4. Lund W. in Pharmaceutical codex. 1994; Pharmaceutical press: London. p. 134-159.
5. Rolland A. Particulate carriers in dermal and transdermal drug delivery: myth or reality, in Pharmaceutipal Particulate Carriers:Therapeutic applications., Hadgraft J. Editor. Marcel Dekker: New York. 1993; 367-421.
6. Florence AT, Attwood D. Physicochemical principles of pharmacy. Second edition ed. Vol. chapters 7-9. 1988, New York: Chapman and Hall. 229-406.
7. Block LH. Medicated applications, in Remington's Pharmaceutical Sciences, Gennaro A R. Editor. Mack: Easton, PA. 1990; 1596-1614.
8. Barry BW. Topical preparations, in Pharmaceutics, Aulton ME. Editor. 1988, Churchill Livingstone: Edinburgh, 381-411.
9. Mezei M, Foldvari M, Gesztes A, Cardinal L, Behl M, Kowalczyk I. Topical liposomal local anesthetics: design optimization and evaluation of formulations. Drug Dev Ind Pharm 1993; 19(19): 2499-2517.
10. Fisher R, Hung O, Mezei M, Stewart R. Topical anaesthesia of intact skin: liposome-encapsulated tetracaine vs EMLA. Br J Anaesth 1998; 81(6): 972-3.
11. Foldvari M, Gesztes A, Mezei M. Dermal drug delivery by liposome encapsulation: clinical and electron microscopic studies: J Microencapsul 1990; 7(4): 479-89.
12. Mezei M. Liposomes in the topical applications of drugs: a review, in Liposomes as drug carriers: recent trends and progress, Gregoriadis G. Editor. Wiley: Chichester. 1988; 663-675.
13. Hung OR, Comeau L, Riley MR, Tan S, Whynot S, Mezei M. Comparative topical anaesthesia of EMLA and liposome-encapsulated tetracaine. Can J Anaesth 1997; 44(7): 707-11.
14. Mezei M, Gulasekharam V. Liposomes a selective drug delivery system for the topical route of administration:Lotion dosage form. Life Sci 1980; 26(18): 1473-1477.
15. Mezei M, Gulasekharam V. Liposomes a selective drug delivery system for the topical route of administration:gel dosage form. J Pharm Pharmacol 1982; 34(7): 473-474.
16. Touitou E, Junginger HE, Weiner ND, Nagai T, Mezei M. Liposomes as carriers for topical and tranadermal delivery. J Pharm Sci 1994; 83: 1189-1203.
17. Mezei M. Liposomes as penetration promoters and localizers of topically applied drugs,.in drug permeation enhancement, theory and applications, D. S. Hsieh, Editor. Marcel Dekker, Inc: Now York. 1994; 171-191.
18. Fresta M, Villari A, Puglisi G, Cavallaro G. 5-Fluorouracil: various kinds of loaded liposomes-encapsulation efficiency, storage stability and fusogenic properties. Int J Pharm 1993; 99: 145-156.
19. Cullis PR, Hope MJ, Bally MB, Madden TD, Mayer LD, Janoff AS. Liposomes as pharmaceuticals, in Liposomes: from biophysics to therapeutics, Ostro MJ. New York. 1983; Dekker: 39-72.
20. Foldvari, M., Attah-Poku, S. K.: US20006165458 (2000).
21. Mezei, M., Gesztes, A.: US4937078 (1990).
22. Mezei, M., Rung, 0.: US5451408 (1996).
23. Nounou MM, El-Khordagui LK, Khalafallah N. Release stability of 5-fluorouracil liposomal concentrates, gels and lyophilized powder. Acta Pol Pharm 2005; 62(5): 381-91.
24. Egbaria K, Weiner N. Topical application of liposomal preparations: 1991.
25. Du Plessis J, Ramachandran C, Weiner N, Muller DG. The influence of Particle size of liposomes on the deposition of drug into skin. Int J Pharm 1994; 103: 277-282.
26. Nagarsenker MS, Joshi AA. Preparation, characterization, and evaluation of liposomal dispersions of lidocaine. Drug Dev Ind Pharm 1997; 23(12): 1159-1165.
27. Jayaraman SC, Ramachandran C, Weiner N. Topical delivery of erythromycin from various formulations: in vivo hairless mouse study: 1996.
28. Vermoeken AJ, Hukkelhoven MW, Vermeesch-Markslag AM, Goos CM, Wirtz P, Ziegenmeyer J. The use of liposomes in the topical application of steroids. J Pharm Pharmacol 1084; 36(5): 334-6.
29. Foldvari M, Jervis B, Oguejiofor CJ. Topical dosage form of liposomal tetracaine: effect of additives on the in vitro release and in vivo efficacy. J Controlled Release 1993; 27: 193-205.
30. Korting HC, Krovekorn W, Klovekorn G, et al. Comparative efficacy and tolerability of econazole liposomal gel 1%, branded econazole conventional cream 1% and generic clotrimazole cream 1% in tinea pedis. Clin Drug Invest 1997; 14: 286-293.
31. Patel B, Mista A. Encapsulation and stability of clofiazimine liposomes. J Microencapsul 1999; 16(3): 357-367.
32. Sanderson NM, Jones MN. Encapsulation of vancomycin and gentumcin within cationic, liposomes for inhibition of growth of Staphylococcus epidermidis. J Drug Target 1996; 4(3): 181-189.
33. Glavas-Dodov M, Fredro-Kumbaradzi E, Goracinova K, Calis S, Simonoska M, Hincal AA. 5-Fluorouracil in topical liposome gels for anticancer treatment-Formulation and Evaluation. Acta Pharm 2003; 53(4); 241-250.
34. Ji HG, Seo BS. Retinyl palmitate at 5% in a cream: its stability, efficacy and effect. Cosmet Toiletries 1999; 114: 61-64, 66-68.
35. Weiner N. Targeted follicular delivery of macromolecules via liposomes. Int J Pharm 1998; 162(Mar 20): 29-38.
36. Gesztes A, Mezei M. Topical anesthesia of the skin by tiposome encapsulated tetracaine. Anesth Analg 1988; 67(11): 1079-81.
37. Moghimi SM, Patel HM. Current progress and future prospects of liposomes in dermal drug delivery. J Micruencapsul 1993; 10(2):155-62.
38. Krowczynski L, Stozek T. Liposomes as drug vehicles in peroutaneous therapy. Pharmazie 1984; 39(9): 627-629.
39. Egbaria K, Ramachandran C, Kittayanond D, Weiner N. Topical delivery of liposomally encapsulated interferon evaluated by in vitro diffusion studies. Antimicrob Agents Chemother 1990; 34(1): 107-10.
40. Weiner N, Martin F, Riaz M. Liposomes as a drug delivery system. Drug Dev Ind Pharm 1989; 15(10): 1523-1554.
41. Miyachi Y, Imamura S, Nina Y. Decreased skin supersuperoxide dismutase activity by a single exposure of ultraviolet radition is reduced by liposomal superoxide dismutase pretreatment. J Invest Dermatol 1987; 89: 111-112.
42. Patel VB, Misra AN, Marfatia YS. Preparation and comparative clinical evaluation of liposomal gel of benzoyl peroxide for acne. 2001; 27(8): 863-70.
43. Birchall JC, Marichal C, Pampbell L, Alwan A, Gumbleton M, et al. Gene expression in an intact ex vivo skin tissue model following percutaneous delivery of cationic liposome-plasmid DNA complexes. 2000; 197(2): 233-238.
44. Raghavachari N, Fahl WE. Targeted gene delivery to skin cells in vivo: a comparative study of liposomes and polymers as delivery vehicles. J Pharm Sci 2002; 91(3): 615-22.
45. Moussaoui N, Cansell M, Denizot A. Marmosomes, marine lipid-based liposomes: physical characterization and potential application in cosmetics. Int J Pharm 2002; 242(1-2), 361-5.
46. Ganesan MG, Weiner-ND, Flynn GL, Ho NF. Influence of liposomal drug entrapment on percutaticous absorption: 1984.
47. Weiner ND, Ganesan MG, Ho NFH. Mechanisms of topical delivery of liposomally entrapped drugs. J Control Release 1985; 2: 61-65.
48. Artmann C, Roding J, Ghyezy M, Pratzel HG. Liposomes from soya phospholipids as percutancous drug carriers: qualitative and in vivo investigation with antibody loaded liposomes. Arzneimitteforschung 1990. 40: 1363-1365.
49. Nounou MM, El-Khordagui LK, Khalafallah N. Effect of various formulation variables on the encapsulation and stability of dibucaine base in multilamellar vesicles. Acta Pol Pharm 2005; 62(5): 369-79.
50. Glavas-Dodov M, Goracinova K, Mladenovska K, Fredro-Kumbaradzi E. Release profile of lidocaine HCl from topical liposomal gel formulation. Int J Pharm 2002; 242(1.2): 381-4.
51. Blume A, Jansen M, Ghzczy M, Gareiss, J. Interaction of phospholipid liposomes with lipid model mixtures for stratum corneum lipids: 1993.
52. Lautenschlager H. Liposomes in dermatological preparations. Part 1: 1990.
53. Brucks, R. M., Duvel, L. A US5720948 (1988).
54. Vyas S, Uchegbu IF. Non ionic surfactant based vesicles (niosomes) in drug delivery. Int J Pharm 1998; 172: 33-70.
55. Hofland H, Bowuwstra JA, Ponec M, et al. Interactions of non-ionic surfactant vesicles with cultured keratinocytes and human skin in vitro: a survey of toxicological aspects and ultrastructural changes in stratum corricum. J Control Release 1991; 16(1): 155-167.
56. Hofland HE, Junginger HE, Bouwstra JA. Mechanism of action of liposomes and niosomes with cell membranes. Pharm Ztg 1991; 136: 9-12, 14-15, 18-24
57. Schreier H, Bouwstra J. Liposomes and niosomes as topical drug carriers: dermal and transdermal drug delivery. J Control Release 1994; 30: 1-15.
58. Planes ME, Gonzalez P, Rodriguez L, Sanchez S, Ceve G. Noninvasive percutencous induction of topical analgesia by a new type of drug carrier, and prolongation of local pain insensitivity by anesthetic liposomes. Anesth Analg 1992; 75(4): 615-21.
59. El Maghraby GM, Williams AC, Barry BW. Skin delivery of oestradiol from lipid vesicles: importance of liposome structure. Int J Pharm 2000; 204(1-2): 159-69.
60. El Maghraby GM, Williams AC, Barry BW. Skin delivery of 5-fluorouracil from ultradeformable and standard liposomes in-vitro. 2001; 3(6): 727.
61. Cevc, G.: US20077175850 (2007).
62. Hofer C.Hartung R, Gobel R, Deering P, Lchmer A, Breul J. New ultrdeformable drug carriers for potential transdermal application of interleukin-2 and interferon-a theoretic and practical aspects. World J Surg 2000; 24(10): 1187-1189.
63. Cevc G, Gebauer D, Stieber J, Schatzlein A, Blume G. Ultraflexible vesicles, Transfersomes, have an extremely low pore penetration resistance and transport therapeutic amounts of insulin across the intact mammalian skin. Biochim Biophys Acta - Biomembranes 1998; 1368(2): 201-15.
64. Touitou E, Dayan N, Bergelson L, Godin B, Eliaz M. Ethosomes - novel vesicular carriers for enhanced delivery: characterization and skin penetration properties. J Control Release 2000; 65(3): 403-18.
65. Godin B, Touitou E. Mechanism of becitracin permeation enhancement through the skin and cellular membranes from an ethosomal carrier. J Control Release 2004; 94(2-3): 365-79.
66. Touitou, E.: US5716638 (1998).
67. Hayward, J. A., Watkins, D. C., Aust D. T.: US20006071535 (2000).
68. Hayward, J. A., Watkins, D. C., Aust, D. T.: US6071535 (1999).
69. Aust, D. T., Hayward, J. A., Wilmott, J., Ross, A.: US6183774 (1999).
70. Allen LV. Basics of compounding: Phonophoresis. Ent J Pharm Compound 2002; 6(5): 362-365.
71. Krowczynski L, Stozek T. Liposomea as drug vehicles in percutaneous therapy. Pharmazie 1984; 39(9): 627-9.
72. Torchilin V, Weissig V. Liposomes: practical approach. 2003; Oxford U Pr N Y. 66-67.
73. Foldvari M, Gesztes A, Mezei M, Cardinal L, Behl M, et al. Topical liposomal local anesthetics: design, optimization and evaluation of formulations. Drug Dev Ind Pharm 1993; 19(19): 2499-2517.
74. Gutierrez De Rubalcava C, Rodriguez JL, Duro R, Alvarez Lorenzo C, Seijo B, et al. Interactions between liposomes and hydroxypropylncthylcellulosc. 2000; 203(2): 99-108.
75. Gabrijelcic V, Sentjurc M. Influence of hydrogels on liposome stability and on the transport of liposome entrapped substances into the skin. Int J Pharm 1995; 118: 207-212.
76. Le Bourlais CA, Treupel Acar L, Rhodes CT, Sado PA, Leverge R. New ophthalmic drug delivery systems. 1995; 21: 19-59.
77. Chandaroy P, Sen A, Hui SW. Temperature-conrolled content release from liposomes encapsulating Pluronic F-127. 2001; 76: 27-31.
78. Gabrijelcic V, Sentjurc M, Kristl J. Evaluation of liposomes as drug carriers into the skin by one-dimensional EPR imaging. Int J Pharm 1990; 62(Jul 15): 75-79.
79. Harwood R. Hydroxypropyl methylcellulose, in hand book of pharmaceutical excipients. 1995; 252-255.
80. Ferreira LS, Ramaldes GA, Nunan EA, Ferreira LA. In vitro skin permeation and retention of paromomycin from liposomes for topical treatment of the cutaneous leishmaniasis. Drug Dev Ind Pharm 2004; 30(3): 289-96.
81. Bhatia A, Kumar R, Katare OP. Tamoxifen in topical liposomes: development; characterization and in-vitro evaluation. J Pharm Pharm Sci 2004; 7(2): 252-59.
82. Pierre MB, Tedesco AC, Marchetti JM, Bentley MV. Stratum corneum lipids liposomes for the topidal delivery of 5-aminolevulinic acid in photodynamic therapy of skin cancer preparation and in vitro permeation study BMC Dermatol 2001; 1: 5.
83. Jaafan MR, Foldvari M. Targeting of liposomes to melanoma cells with high levels of ICAM-1 expression through adhesive peptides from immunoglobulin domains. J Pharm Sci 2002; 91(2): 396-404.
84. Aust D, Judd C, Wilmott J. Stability enhancement of retinol through ancapsulation in cationic vesicles. J Cosmetic Sci 2000; 51(1): 52-53.
85. Vyas SP, Singh RP, Jain S, et al. Non-ionic surfactant based vesicles (niosomes) for non-invasive topical genetic immunization against hepatitis B. Int J Pharm 2005; 296(1-2). 80-86.
86. Fang JY, Hong CT, Chiu WF, Wang YY. Effect of liposomes and niosomes on skin permeation of enoxacin. Int J Pharm 2001; 219(1-2): 61-72.
87. Cevc G, Blume G. Biological activity and characteristics of triamcinoloneacetonide formulated with the self-regulating drug carriers, Transfersomes. Biochim Biophys Acts 2003; 1614(2): 156-64.
88. Cevc G. Transdermal drug delivery of insulin with ultradeformable carriers. Clin Pharmacokinet 2003; 42(5): 461-74.
89. Cevc G, Blume G. Hydrocortisone and dexamethasone in very deformable drug carriers have increased biological potency, prolonged effect, end reduced therapeutic dosage. Biochim Biophys Acta 2004; 1663(1-2): 61-73.
90. Mahor S, Rawat A, Dubey PK, et al. Cationic transfersomes based topical genetic vaccine against hepatitis B, Int J Pharm 2007; 4(4): 341-348.
91. Elsayed MM, Abdallah OY, Nagger VF, Khalafallah NM. Deformable liposomes and ethosomes as carriers for skin delivery of ketotifen. Pharmazie 2007; 62(2): 133-37.
92. Ainbinder D, Touitou E. Testosterone ediosomes for enhanced transdermal delivery. Drug Deliv 2005; 12(5): 297-303.
93. Godin B, Touitou E. Erythromycin ethosomal systems: physicochemical characterization and enhanced antibacterial activity. Curr Drug Deliv 2005; 2(3): 269-75.
94. Paolino D, Lucania G, Mardente D, Alhaique F, Fresta M. Ethosomes for skin delivery of ammonium glycyrrhizinate: in vitro percutaneous permeation through human skin and in vivo anti-inflammatory activity on human volunteers. J Control Release 2005; 106(1-2): 99-110.
95. Zuidam NJ, winden EV, Vrueh RD, Crommelin DJ. Stability, storage, and sterilizahon of liposomes., in Liposomes: a practical approach, Weissig V. Editor. 2003, Oxford University Press: NewYork. 149-165.
96. Tabandeh H and Ghasemi Z. Preparation of urea-containing stable plurilamellar liposomes and studying the efficacy of cholesterol on their encapsulation efficiency and release rate. DARU 2001; 9(1 & 2): 28-32.
97. Fransen GJ, Salemink PJ, and Crommelin DJ. Critical parameters in freezing of liposomes: Int J Pharm 1986; 33: 27-35.
98. Tsukada K, Ueda CT, and Ukada R. Preparation of liposome encapsulated antitumor drugs relationship between lipophilicity and invitro drug release. Chem Pharm Bull 1984; 32: 1929-1935.
99. Ozer AY and Talsma H. Preparation and stability of liposomes containing 5-fluorouracil. Int J Pharm 1989; 55(Oct 15): 185-19l.
100. Sharma A and Sharma US. Liposomes in drug delivery: progress and limitations. Int J Pharm 1997; 154(Aug 26): 123-140.
101. Martin FJ. Pharmaceutical manufacturing of liposomes, in Specialized drug delivery system, manufacturing and production technology, New York Tyle P. Editor. 1990, Marcel Dekker Inc. and Basel. 267-316.
102. Nounou MM, El-Kourdagui L, Khallafallah N, Release Stability of 5-fluorouracil liposomal concentrates, gets and lyophilized powder. Acta Poloniae Pharmaceut-Drug Res 2005; 62(5); 381-391.